These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 18707164)

  • 1. Quantum mechanical studies of residue-specific hydrophobic interactions in p53-MDM2 binding.
    Ding Y; Mei Y; Zhang JZ
    J Phys Chem B; 2008 Sep; 112(36):11396-401. PubMed ID: 18707164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into mechanism of small molecule inhibitors of the MDM2-p53 interaction: molecular dynamics simulation and free energy analysis.
    Chen J; Wang J; Xu B; Zhu W; Li G
    J Mol Graph Model; 2011 Sep; 30():46-53. PubMed ID: 21764342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational analysis of spiro-oxindole inhibitors of the MDM2-p53 interaction: insights and selection of novel inhibitors.
    Huang W; Cai L; Chen C; Xie X; Zhao Q; Zhao X; Zhou HY; Han B; Peng C
    J Biomol Struct Dyn; 2016; 34(2):341-51. PubMed ID: 25808617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics simulations studies and free energy analysis on inhibitors of MDM2-p53 interaction.
    Niu RJ; Zheng QC; Zhang JL; Zhang HX
    J Mol Graph Model; 2013 Nov; 46():132-9. PubMed ID: 24211465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations.
    Espinoza-Fonseca LM; Trujillo-Ferrara JG
    Biopolymers; 2006 Nov; 83(4):365-73. PubMed ID: 16817233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing the Free-Energy Landscape of MDM2 Protein-Ligand Interactions by Steered Molecular Dynamics Simulations.
    Hu G; Xu S; Wang J
    Chem Biol Drug Des; 2015 Dec; 86(6):1351-9. PubMed ID: 26032728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting mechanism of small molecule toward the p53-MDM2 interaction: A molecular dynamic exploration.
    Chen J; Wang J; Pang L; Zhu W
    Chem Biol Drug Des; 2018 Oct; 92(4):1763-1777. PubMed ID: 29877036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thermodynamic and computational studies on the binding of p53-derived peptides and peptidomimetic inhibitors to HDM2.
    Grässlin A; Amoreira C; Baldridge KK; Robinson JA
    Chembiochem; 2009 May; 10(8):1360-8. PubMed ID: 19408261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A computational analysis of the binding model of MDM2 with inhibitors.
    Hu G; Wang D; Liu X; Zhang Q
    J Comput Aided Mol Des; 2010 Aug; 24(8):687-97. PubMed ID: 20490618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a retroinverso p53 peptide as an inhibitor of MDM2.
    Sakurai K; Chung HS; Kahne D
    J Am Chem Soc; 2004 Dec; 126(50):16288-9. PubMed ID: 15600307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-operative intra-protein structural response due to protein-protein complexation revealed through thermodynamic quantification: study of MDM2-p53 binding.
    Samanta S; Mukherjee S
    J Comput Aided Mol Des; 2017 Oct; 31(10):891-903. PubMed ID: 28871352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-site regulation of MDM2 E3-ubiquitin ligase activity.
    Wallace M; Worrall E; Pettersson S; Hupp TR; Ball KL
    Mol Cell; 2006 Jul; 23(2):251-63. PubMed ID: 16857591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2.
    Dastidar SG; Lane DP; Verma CS
    J Am Chem Soc; 2008 Oct; 130(41):13514-5. PubMed ID: 18800837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydrophobic Interactions Are a Key to MDM2 Inhibition by Polyphenols as Revealed by Molecular Dynamics Simulations and MM/PBSA Free Energy Calculations.
    Verma S; Grover S; Tyagi C; Goyal S; Jamal S; Singh A; Grover A
    PLoS One; 2016; 11(2):e0149014. PubMed ID: 26863418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting protein-protein interactions: lessons from p53/MDM2.
    Murray JK; Gellman SH
    Biopolymers; 2007; 88(5):657-86. PubMed ID: 17427181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational studies and peptidomimetic design for the human p53-MDM2 complex.
    Zhong H; Carlson HA
    Proteins; 2005 Jan; 58(1):222-34. PubMed ID: 15505803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction.
    Thayer KM; Beyer GA
    PLoS One; 2016; 11(3):e0147806. PubMed ID: 26992014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Modeling Investigation of Folic Acid Conjugation to MDM2 Inhibitors for Enhanced Cellular Uptake and Target Binding.
    Patil SP; Kerezsi CR; Hicks BM; Jednorski AH
    Curr Comput Aided Drug Des; 2015; 11(3):258-65. PubMed ID: 26265252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
    Chène P
    Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft.
    Showalter SA; Bruschweiler-Li L; Johnson E; Zhang F; Brüschweiler R
    J Am Chem Soc; 2008 May; 130(20):6472-8. PubMed ID: 18435534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.